Current Document Type: HighlightsVideoPage Subgroup Analysis of Elderly Patients With Diffuse Large B-Cell Lymphoma in the Phase III POLARIX Study - JADPRO

Watch More Highlights

Oxana Megherea, PharmD, BCOP, of Penn Medicine, University of Pennsylvania Health System, discusses a subgroup analysis of elderly patients enrolled in the phase III POLARIX study. In POLARIX, polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) significantly improved progression-free survival compared with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP), with a similar safety profile in patients aged 18 to 80 years with previously untreated diffuse large B-cell lymphoma (DLBCL). In this subgroup analysis, Pola-R-CHP and R-CHOP demonstrated similar safety profiles in patients aged ≥ 70 years with previously untreated DLBCL (Abstract 7518). 

Copyright © 2010-2022 Harborside Press, LLC All rights reserved.               
Home | Current Issue | Previous Issue | Submissions | About JADPRO | Advertising | Privacy Policy | Contact | Copyright Notice/Disclaimer | Subscribe
Bot trap - Don't go here
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.